Company intelligence / Profile preview

Sparrow Pharmaceuticals

Portland, Oregon, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Clofutriben, Sparrow’s lead oral small molecule HSD-1 inhibitor, is in Phase 2b for treatment-resistant type 2 diabetes with elevated cortisol, ongoing Phase 2 for polymyalgia rheumatica (with prednisolone), and has completed Phase 2 with orphan drug designation for endogenous Cushing’s syndrome. Initial trials in adrenal tumor went unproductive, but academic studies persist. Interim data in PMR and ongoing readouts expected in 2027 for diabetes trial[1][3][4][6].

Therapeutic areas: EndocrinologyRheumatology
Modalities: Small molecule
Industry: Biotech

Partnerships

Oxford University (autonomous cortisol secretion academic collaboration)Sheffield University (academic collaboration for adrenal tumor studies)[6]Astellas (asset licensing for corticosteroid side effects)[5]

Beyond the preview

Go deeper on Sparrow Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sparrow Pharmaceuticals.

Explore the full profile